Lupin enters into partnership with Foncoo for China

Mumbai: Global pharma major, Lupin Limited today announced that the company has entered into a partnership with Shenzhen Foncoo Pharmaceutical Co. Ltd.

According to the release, this is Lupin's first partnership arrangement in China and reinforces Lupin's commitment to bringing high quality generic and complex generic medicines to patients around the world.

Dr. Fabrice Egros, President – Growth Markets, Lupin said, "Lupin continues to invest in key growth markets. With China's growing commitment to affordable and accessible healthcare, Lupin is committed to serving the healthcare needs of the Chinese population by providing high quality generic and complex generic products. We are very excited about our partnership with Foncoo. We will continue exploring additional partnership opportunities in China to leverage our global portfolio including complex generics and specialty medicines."   

Read also: Namuscla recommended by NICE for treatment of myotonia in adults with NDM: Lupin       

Mr. Peng Yan, General Manager, Foncoo said, "Foncoo's successful experiences on importing registration and marketing of the generic formulations and Lupin's strong capability of making high quality medicines make us perfect match to each other and our collaboration will have a bright future most likely. We expect that the successful launch of our first product in China will come smoothly and soon. We will also continue exploring more opportunities to work with Lupin for providing more and more high-valued and complex medicines to the Chinese physicians and patients."